Aksel Siva, EAN 2019 – Treatment strategies in multiple sclerosis
Aksel Siva (Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey), a valued member of our European editorial board, talks to us about the topic of the interactive session he participated in focusing on treatment strategies in progressive multiple sclerosis.
1. What criteria should guide a clinician’s decision as to when to initiate and/or escalate disease-modifying treatment in progressive multiple sclerosis (MS)? (0:04)
2. What is the current status of research into predictors in progressive MS? (1:40)
Speaker disclosure: Aksel Siva has received honoraria for educational presentations and consultation fees from Novartis, Sanofi-Genzyme, F. Hoffmann-La Roche, Biogen Idec/Gen Pharma of Turkey, Merck Serono and Teva; received travel and registration coverage for attending several national or international congresses or symposia from Merck Serono, Biogen Idec/Gen Pharma of Turkey, Genzyme and , F. Hoffmann-La Roche.
Filmed at the 5th Congress of the European Academy of Neurology (EAN), Oslo, Norway, June 2019.
Share this Video
Related Videos In Multiple Sclerosis
Barry Singer, ECTRIMS 2022: Diroximel fumarate for relapsing-remitting multiple sclerosis – Phase 3 results from EVOLVE-MS-1
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite as dimethyl fumarate. Diroximel fumarate has similar efficacy and safety […]
Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study
The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with […]
Dominic Shadbolt: ECTRIMS Patient perspective – Lifestyle interventions as part of a management plan for MS
We welcome Dominic Shadbolt, a patient advocate in multiple sclerosis (MS), and founder of theMSguide.com. Dominic joins touchNEUROLOGY to share his perspective on being a patient advocate at the annual ECTRIMS congress, and highlights from the most salient presentations. In this interview, Dominic highlights the lifestyle interventions that people living with MS can undertake as […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!